GSK, RSV and Shingles
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses compared with separate administration of the vaccines.
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co-administered in adults aged 50 and older.
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older. The British pharma giant said Wednesday a Phase 3 study evaluating RSV vaccine Arexvy co-administered with Shingrix met the primary endpoint,
Free RSV vaccines for pregnant women could be coming next year — here's what you need to know
RSV is a highly infectious virus that is the most common cause of respiratory infections in children. A free vaccine could ...
The American Journal of Managed Care5d
New RSV Vaccine Is Likely Cost-Effective for Older Adults, Study Finds
Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...
After years of advocacy by a pediatrician, all Nunavut babies to get RSV immunization
The Nunavut government says it will provide immunization against respiratory syncytial virus to all infants in the territory ...
Medscape9d
For Which Adults Are RSV Vaccination Programs Cost-Effective?
Medical risk-based approaches outperformed age-based strategies, even when vaccine prices were low, the study authors said.
WGAL10d
Pulmonologist talks about RSV: Symptoms, who's most at risk, effectiveness of vaccine
A UPMC pulmonologist talks about the symptoms, explains who is most at risk for a severe infection, and tells us how ...
CNN6d
What to know about the vaccines available this respiratory virus season
Last year was the first year that the US had vaccines available to protect against all three major respiratory viruses — Covid-19, flu and RSV — but vaccine uptake was low for the season.
RSV vaccine rolled out in Jersey to combat respiratory illnesses
The Respiratory Syncytial Virus (RSV) vaccine will be rolled out to some older islanders as well as pregnant women. | ITV ...
Yahoo Style Canada6d
Should Canadian seniors get the RSV vaccine? What the latest study says about cost and benefits
With the arrival of new vaccines for respiratory syncytial virus (RSV), Canadian seniors are faced with a critical decision: Is it worth getting the shot, especially if it’s not covered by ...
NHS issues new vaccine plea to avoid 'tripledemic' of viruses
NHS bosses have urged Britons to get vaccinated this autumn to prevent a “tripledemic” of flu, covid-19 and respiratory ...